



A Public Entity

Inland Empire Health Plan

PHARMACY TIMES

BY IEHP PHARMACEUTICAL SERVICES DEPARTMENT

October 1, 2020

IEHP Formulary Changes: August 2020 P&T Update

Dear IEHP Provider

We would like to inform you of the following changes to the 2020 IEHP Formulary that were approved by the Pharmacy and Therapeutics Subcommittee in August 2020. Changes will take effect on October 1, 2020.

AF = Add to Formulary	PA = Prior Authorization
AR = Age Restriction	QL = Quantity Limit
BOLD = Brand Name	R-C1 = Remove Code 1 restriction
C1 = Code 1 drugs are restricted to certain medical conditions or specific circumstances	RF = Remove from Formulary
DS = Days Supply	R-PA = Remove Prior Authorization
F = Formulary	R-QL = Remove Quantity Limit
NF = Non-formulary	ST = Step Therapy

NOTE: IEHP is a generic mandated health plan. Brand name drugs are not covered unless indicated or if generic is not available. The FDA recommended maximum dosage limit is applied.

Miscellaneous Drug Class Updates				
Drug Name	Strength and Formulation	Formulary Status	AR/ST/QL/C1 Status	PA Criteria Status
Mesalamine DR	400mg capsule	F		Remove PA
Firmagon (degarelix acetate)	1.2g tablet	F		Remove PA
Fluarix, Fluzone, Fluzone High-Dose, Flublok, Flarix, Afluria, FluLaval, Fluid, Flucelvax (influenza vaccine 1920-1921)	injection	F	AR: 18 yrs old+	

10801 6th St., Suite 120, Rancho Cucamonga, CA 91730
Tel (909) 890-2049 Fax (909) 890-2058
Visit our web site at: www.iehp.org

A Public Entity



A Public Entity

Inland Empire Health Plan

Flumist Quadrivalent (influenza vaccine, live, 2020-2021)	suspension, 0.2 mL in single dose intranasal sprayer	F	AR: 18 yrs old+	
---	--	---	-----------------	--

Clinical Practice Guideline Updates		
Clinical Practice Guideline	Academy/Association	Status
Attention Deficit Hyperactivity Disorder - Pediatrics	American Academy of Pediatrics (2011)	Update
Osteoarthritis - Nonpharmacologic and Pharmacologic Therapies in Osteoarthritis of the Hand, Hip and Knee	American College of Rheumatology (2019)	Update
Asthma GINA	Global Initiative for Asthma (2020)	Update
Chronic Obstructive Pulmonary Disease COPD	Global Initiative for Chronic Obstructive Lung Disease (2020)	Update

For any questions, suggestions, or if you would like a printed copy of the IEHP Formulary Book or Clinical Practice Guideline, please call us at (909) 890-2049. As a reminder, the updated formulary information and Clinical Practice Guidelines are available at www.iehp.org.

Sincerely,
IEHP Pharmaceutical Services